Pediatric allergic rhinitis: Factors affecting treatment choice

Ear, Nose and Throat Journal

Volumn 84, Issue 3, 2005, Pages 163-168

  Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; DECONGESTIVE AGENT; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; FEXOFENADINE; GLUCOCORTICOID; HYDROXYZINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; PHENBENZAMINE; PROMETHAZINE; TERFENADINE; UNCLASSIFIED DRUG; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST;

ALLERGIC RHINITIS; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEARNING DISORDER; MUCOSAL DRYNESS; PREVALENCE; QT PROLONGATION; SEDATION; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; TREATMENT PLANNING; URINE RETENTION; XEROSTOMIA; CHILD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; INFANT; MALE; PERENNIAL RHINITIS; PRESCHOOL CHILD; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; MALE; RHINITIS, ALLERGIC, PERENNIAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20844439192     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556130508400314     Document Type: Article

References (48)

1. Management of Allergic and Nonallergic Rhinitis. Summary, Evidence Report/Technology Assessment: Number 54, May 2002. Rockville, Md.: U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality, www.ahrq.gov/clinic/epcsums/rhinsum.htm (accessed Feb. 2, 2005).
2. Druce HM, Kaliner MA. Allergic rhinitis. JAMA 1988;259:260-3.
3. Fagin J, Friedman R, Fireman P. Allergic rhinitis. Pediatr Clin North Am 1981;28:797-806.
4. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71:121-6.
5. Marshall PS, Colon EA. Effects of allergy season on mood and cognitive function. Ann Allergy 1993;71:251-8.
6. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-23.
7. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108(1 suppl):S45-53.
8. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 suppl):S147-334.
9. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209-13.
10. Frederick JM, Warner JO, Jessop WJ, et al. Effect of a bed covering system in children with asthma and house dust mite hypersensitivity. Eur Respir J 1997;10:361-6.
11. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003;349:237-46.
12. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111:S835-42.
13. Wahn U, Meltzer EO, Finn AF, Jr., et al. Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003;111:763-9.
14. Boner AL, Miglioranzi P, Richelli C, et al. Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis. Allergy 1989;44:437-41.
15. Lutsky BN, Klose P, Melon J, et al. A comparative study of the efficacy and safety of loratadine syrup and terfenadine suspension in the treatment of 3- to 6-year-old children with seasonal allergic rhinitis. Clin Ther 1993;15:855-65.
16. Pearlman DS, Lumry WR, Winder JA, Noonan MJ. Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: A randomized, double-blind, placebo-controlled study. Clin Pediatr (Phila) 1997;36:209-15.
17. Tinkelman D, Kemp J, Mitchell D, et al. Treatment of seasonal allergic rhinitis in children with cetirizine or chlorpheniramine: A multicenter study. Pediatr Asthma Allergy Immunol 1996;10:9-17.
18. Allegra L, Paupe J, Wieseman HG, Baelde Y. Cetirizine for seasonal allergic rhinitis in children aged 2-6 years. A double-blind comparison with placebo. Pediatr Allergy Immunol 1993;4:157-61.
19. Simons FE, Silas P, Portnoy JM, et al. Safety of cetirizine in infants 6 to 11 months of age: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2003;111:1244-8.
20. Astelin (Azelastine product information package insert). Somerset, N.J.: MedPointe Pharmaceuticals, 2003. www.astelin.com/AstelinPI.pdf (accessed Feb. 2, 2005).
21. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: Suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990;86(4 Pt 1):540-7.
22. Rivest J, Despontin K, Ghys L, et al. Pharmacological modulation by cetirizine and ebastine of the cutaneous reactivity to histamine. Dermatologica 1991;183:208-11.
23. Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002;88:190-7.
24. Frossard N, Purohit A, Kovacs S, et al. Fexofenadine is superior to loratadine and desloratadine in onset of action of histamine-induced wheal and flare inhibition. Ann Allergy Asthma Immunol 2003;90:124.
25. Purohit A, N'Gom AS, Deslandes B, et al. Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Ann Allergy Asthma Immunol 2004;93:562-67.
26. Simons FE, Simons KJ. Peripheral H1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997;79:530-2.
27. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: Confirmation of a test system. Ann Allergy Asthma Immunol 2001;87:474-81.
28. Simons FE, Semus M, Goritz SS, Simons KJ. H1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr Allergy Immunol 2003;14:207-11.
29. Litovitz T, Holm K, Bailey K, Schmitz B. Demographic profile of exposure cases by generic category of substances and products: Nonpharmaceuticals. Annual Report of the American Association of Poison Control Centers National Data Collection System. 1991:477-89.
30. Goetz CM, Lopez G, Dean BS, Krenzelok EP. Accidental childhood death from diphenhydramine overdosage. Am J Emerg Med 1990;8:321-2.
31. Ridout SM, Tariq SM. Cetirizine overdose in a young child. J Allergy Clin Immunol 1997;99(6 Pt 1):860-1.
32. Vuurman EF, van Veggel LM, Sanders RL, et al. Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;76:247-52.
33. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: Validation studies in allergic rhinitis. Clin Drug Invest 1996;11:278-88.
34. Bender BG, McCormick DR, Milgrom H. Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine. J Pediatr 2001;138:656-60.
35. Weiler JM, Bloomfield JR, Woodworm GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 2000;132:354-63.
36. Nicholson AN, Handford AD, Turner C, Stone BM. Studies on performance and sleepiness with the H1-antihistamine, desloratadine. Aviat Space Environ Med 2003;74:809-15.
37. Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - A pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253-60.
38. Graft DF, Bernstein DI, Goldsobel A, et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:22-6.
39. Ng KH, Chong D, Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: A randomized, double-blind, placebo-controlled comparative study. Pediatrics 2004;113:e116-21.
40. Hindmarch I, Shamsi Z. Antihistamines: Models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999;29(suppl 3):133-42.
41. Shamsi Z, Hindmarch I. Sedation and antihistamines: A review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000;15(S1):S3-S30.
42. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987;59(6 Pt 2):4-8.
43. Simons FE, Bergman JN, Watson WT, Simons KJ. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996;98(6Pt 1):1062-4.
44. Salmun LM, Herron JM, Banfield C, et al. The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clin Ther 2000;22:613-21.
45. Diepgen TL. Long-term treatment with cetirizine of infants with atopic dermatitis: A multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002;13:278-86.
46. Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines. Clin Allergy Immunol 2002;17:389-419.
47. Zareba W, Moss AJ, Rosero SZ, et al. Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 1997;80:1168-73.
48. Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 1999;29(suppl 3):212-16.